


BLX-155: Major Market Opportunity, Proven Mechanism of Action



Indications

Peripheral blood clots

- Acute peripheral arterial disease (aPAO)
- Deep vein thrombosis (DVT)
- Hemodialysis graft thrombosis (HGT)

Opportunity

- Thrombosis affects 50 million people
- Multi-billion \$ market
- tPA has limited effectiveness in older/longer clots
- Indirect action
- Risk (brain bleeds)

Best in Class

More effective:

- Direct acting
- High binding affinity

Safe:

- Natural safety screen
- Lower risk of bleeding

As the body's natural clot buster, recombinant full-length plasmin has been pursued for more than two decades. Only the LEX System can produce this complex protein at commercial levels